Quanticate

quanticate.com

Quanticate, with headquarters in the UK and USA, is a specialist Clinical Research Organization (CRO) primarily focused on the management, analysis.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

SPOTLITE360 INTRODUCES PHARMACEUTICAL INDUSTRY INITIATIVE FOR SUPPLY CHAIN TRACKING, TRACING, AND SUSTAINABILITY

Spotlite360 | July 07, 2021

news image

SPOTLITE360 TECHNOLOGIES, INC. is happy to announce that it has started an initiative to provide tailored supply chain tracing and tracking solutions for pharmaceutical companies, for which it is now in contract discussions with pharmaceutical firms. This effort coincides with an impending regulatory shift in the USD 1.3 trillion pharmaceutical industry1 that will require companies to comply with the Drug Supply Chain Security Act (“DSCSA”), which requires the deployment of electroni...

Read More

Pharmacy Market

ASTELLAS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 LONG-TERM SAFETY STUDY OF FEZOLINETANT IN MAINLAND CHINA

Astellas Pharma Inc. | September 05, 2022

news image

Astellas Pharma Inc. announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. MOONLIGHT 3 is a 52-week single-arm Phase 3 clinical trial ...

Read More

Business Insights

SIGNET HEALTHCARE PARTNERS COMPLETES GROWTH EQUITY INVESTMENT IN JUNO PHARMACEUTICALS CORP

Juno Pharmaceuticals | February 25, 2022

news image

Juno Pharmaceuticals Corp a Canadian specialty generics pharmaceuticals company, announced that it has received a strategic growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare growth equity firm. Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio and to accelerate growth. “We are very pleased with the opportunity to partner with the Juno management te...

Read More

Business Insights

ARS PHARMACEUTICALS EXPANDS EXECUTIVE LEADERSHIP TEAM WITH ADDITION OF PHARMACEUTICAL COMMERCIALIZATION VETERANS

ARS Pharmaceuticals, Inc. | February 10, 2022

news image

ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive leadership team with the appointments of Harris Kaplan as executive vice president, commercial strategy and Daniel Relovsky as senior vice president, sales and marketing. Mr. Kaplan and Mr. Relovsky, accomplished industry veterans with proven track r...

Read More
news image

Pharmacy Market

SPOTLITE360 INTRODUCES PHARMACEUTICAL INDUSTRY INITIATIVE FOR SUPPLY CHAIN TRACKING, TRACING, AND SUSTAINABILITY

Spotlite360 | July 07, 2021

SPOTLITE360 TECHNOLOGIES, INC. is happy to announce that it has started an initiative to provide tailored supply chain tracing and tracking solutions for pharmaceutical companies, for which it is now in contract discussions with pharmaceutical firms. This effort coincides with an impending regulatory shift in the USD 1.3 trillion pharmaceutical industry1 that will require companies to comply with the Drug Supply Chain Security Act (“DSCSA”), which requires the deployment of electroni...

Read More
news image

Pharmacy Market

ASTELLAS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 LONG-TERM SAFETY STUDY OF FEZOLINETANT IN MAINLAND CHINA

Astellas Pharma Inc. | September 05, 2022

Astellas Pharma Inc. announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. MOONLIGHT 3 is a 52-week single-arm Phase 3 clinical trial ...

Read More
news image

Business Insights

SIGNET HEALTHCARE PARTNERS COMPLETES GROWTH EQUITY INVESTMENT IN JUNO PHARMACEUTICALS CORP

Juno Pharmaceuticals | February 25, 2022

Juno Pharmaceuticals Corp a Canadian specialty generics pharmaceuticals company, announced that it has received a strategic growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare growth equity firm. Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio and to accelerate growth. “We are very pleased with the opportunity to partner with the Juno management te...

Read More
news image

Business Insights

ARS PHARMACEUTICALS EXPANDS EXECUTIVE LEADERSHIP TEAM WITH ADDITION OF PHARMACEUTICAL COMMERCIALIZATION VETERANS

ARS Pharmaceuticals, Inc. | February 10, 2022

ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive leadership team with the appointments of Harris Kaplan as executive vice president, commercial strategy and Daniel Relovsky as senior vice president, sales and marketing. Mr. Kaplan and Mr. Relovsky, accomplished industry veterans with proven track r...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us